ArticleJAMA network open2026

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Martin Zarba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.